CHE 59700: Analytical Approach to Healthcare Delivery (Fall 2020)

A. Instructor. William R. Clark, M.D.

B. Course Description. This course provides a “real world” overview of healthcare delivery in the United States (US). The topics covered include the major medical product segments, regulatory framework, and financial considerations, including costs, health insurance, and reimbursement. Following a focused review of relevant physiology and pathophysiology, a series of critical medical conditions having the highest impact on the US healthcare system are discussed. Clinical cases illustrating these conditions along with case studies designed to provide practical examples of healthcare developments and challenges are included. A number of emerging healthcare developments, including precision medicine, artificial intelligence, digital health, and value-based care, are addressed. Finally, an important aspect of the course is a team project, occurring over the last half of the semester and consisting of two presentations and a final report (in lieu of examinations).

C. Course requirements. The course is open to all undergraduate students and all students enrolled in the Graduate School. BIOL 23000 or equivalent course is recommended but not mandatory.

D. Recommended (NOT REQUIRED) Texts.
   - Crowley's An Introduction to Human Disease: Pathology and Pathophysiology Correlations, Edited by Emily Reisner, Howard Reisner, Jones and Bartlett Learning, 2017, 10th ed, ISBN 978-1284050233

E. Course Learning Outcomes.
   - Evaluate the impact of the following conditions, from both a clinical and resource utilization (cost) perspective: coronary artery disease, heart failure, diabetes, cancer, obesity, Alzheimer’s disease, chronic kidney disease, stroke, arthritis, sepsis, and acute kidney injury.
   - Analyze the major segments of medical products (pharmaceutical/biotechnology compounds and medical devices) along with the regulatory framework applying to each of these segments.
   - For the biopharmaceutical industry, determine the major components of the drug development process and the manner in which drug pricing factors into the risk/reward equation.
   - Assess US health economics by identifying the major cost drivers in the healthcare system (hospital care; physician costs; drugs and other medical products).
   - Formulate a basic understanding of the sources of health insurance coverage in the US, including the differences between government-based (Medicare/Medicaid) and commercial payers.
   - Explain several evolving trends which have the potential to influence healthcare substantially in the future, including precision medicine, artificial intelligence, digital health, and value-based care.

F. Course Meeting Schedule.
   Lectures: Tuesday/Thursday 4:30-5:45 PM
   Presentation 1: TBD
   Presentation 2: TBD
   Final Report due: December 11
At the approximate mid-point of the semester, students will assemble into groups of 3-4 and choose a high-impact clinical condition to study. Each group will provide two progress updates (Presentations 1 and 2) during the course of the semester in lieu of formal examinations. A complete written summary of each group’s assessment (Final Report) will be due at semester’s end in lieu of a final examination.

G. Instructor Contact Information.

Professor William R. Clark – Email: clarkw@purdue.edu, Telephone: (765) 496-8647 (office); (317) 691-1438 (cell)
Office: FRNY 2158
Office Hours: TBD

H. Assessment of Course Outcomes. A weighted average grade will be calculated as follows.

- Homework assignments (2): 20% of total
- Presentations (2): 40% total
- Final report: 40% of total

The grading scale will be as follows.

- A: 100 – 85% of the weighted points
- B: 84.9 – 75% of the weighted points
- C: 74.9 – 65% of the weighted points
- D: 64.9 – 55% of the weighted points
- F: Less than 55% of the weighted points

Note that students with grades within 3 weighted percentage points of either the upper or lower bounds of a grade range listed above will receive a “plus” or “minus” mark, respectively, after his/her score (e.g., scores between 75% and 78% of the total weighted points would earn an B–). Marks of an A– will not be given.

Group projects

Student groups may assess a high-impact clinical condition from the list of those discussed in class or another one (with instructor approval). In either case, each group should plan to meet with Professor Clark before beginning work on the project to set expectations. The assessment will include the clinical characteristics of the disorder along with its causes, demographics, and current treatment – these topics will be presented in Presentation 1. With Professor Clark or another engineering faculty member serving as a mentor, an unmet clinical need for the disorder will be identified along with an engineering-based solution for the problem – these considerations will be the focus of Presentation 2. For a particular disorder, the engineering approach can have a direct clinical effect (e.g., improved medical device treatment) or indirect clinical effect (e.g., novel manufacturing approach for pharmaceuticals).

I. Lecture Topics.

- Class #1: Introduction to the US healthcare system; basic principles
- Class #2: Cardiac disease (hypertension; congestive heart failure; coronary artery disease)
- Class #3: Obesity/metabolic syndrome
- Class #4: Diabetes
- Class #5: Cancer
- Class #6: Chronic kidney disease/end-stage renal disease
- Class #7: Clinical case #1
- Class #8: Neurologic disease (Alzheimer’s disease; stroke)
- Class #9: Inflammatory/autoimmune disorders
- Class #10: Liver disease (chronic/cirrhotic liver disease; non-alcoholic steatohepatitis: NASH)
- Class #11: ICU disorders – sepsis; acute kidney injury
- Class #12: Clinical case #2
- Class #13: Overview of biopharmaceutical industry (I)
- Class #14: Overview of biopharmaceutical industry (II)
- Class #15: Drug Discovery*
- Class #16: Drug manufacturing*
- Class #17: Case study: Medical device company (Cook Biotech)*
- Class #18: Overview of medical device industry (I)
- Class #19: Overview of medical device industry (II)
- Class #20: Health economics (spending/financing)
- Class #21: Health insurance
- Class #22: Principles of clinical/biomedical research
- Class #23: Case study: Management of clinical data/electronic medical record
- Class #24: Emerging Trends (I): Precision medicine
- Class #25: Emerging trends (II): Artificial intelligence; digital health
- Class #26: Case study: Opioid crisis (scope of problem and potential solutions)*
- Class #27: Emerging trends (III): Value-based care; risk-sharing initiatives
- Class #28: Case study: Entrepreneurship in medicine (formation of a start-up)*

*: Guest speakers